Industry
Biotechnology
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Loading...
Open
5.61
Mkt cap
307M
Volume
433K
High
5.72
P/E Ratio
-3.98
52-wk high
6.19
Low
5.18
Div yield
N/A
52-wk low
0.72
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 10:54 am
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 11:31 am
Portfolio Pulse from Benzinga Newsdesk
July 17, 2024 | 10:50 am
Portfolio Pulse from Avi Kapoor
June 14, 2024 | 6:13 pm
Portfolio Pulse from Benzinga Insights
June 14, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
June 14, 2024 | 12:19 pm
Portfolio Pulse from Benzinga Insights
June 14, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 11:25 am
Portfolio Pulse from Avi Kapoor
June 14, 2024 | 10:08 am
Portfolio Pulse from Avi Kapoor
June 14, 2024 | 9:50 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.